Rani Therapeutics Inc. (RANI)
1.18
0.05 (4.42%)
At close: Apr 11, 2025, 3:59 PM
1.19
0.85%
After-hours: Apr 11, 2025, 04:24 PM EDT
4.42% (1D)
| Bid | 1.15 |
| Market Cap | 67.83M |
| Revenue (ttm) | 1.03M |
| Net Income (ttm) | -30.02M |
| EPS (ttm) | -1.05 |
| PE Ratio (ttm) | -1.12 |
| Forward PE | -1.84 |
| Analyst | Buy |
| Ask | 1.29 |
| Volume | 139,677 |
| Avg. Volume (20D) | 842,403 |
| Open | 1.19 |
| Previous Close | 1.13 |
| Day's Range | 1.16 - 1.24 |
| 52-Week Range | 1.03 - 8.75 |
| Beta | 0.14 |
About RANI
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-al...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 30, 2021
Employees 140
Stock Exchange NASDAQ
Ticker Symbol RANI
Website https://www.ranitherapeutics.com
Analyst Forecast
According to 5 analyst ratings, the average rating for RANI stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 747.46% from the latest price.
Stock Forecasts2 months ago
+14.58%
Rani Therapeutics Holdings shares are trading high...
Unlock content with
Pro Subscription
2 months ago
+5.11%
Rani Therapeutics Holdings shares are trading higher after the company announced new pharmacokinetic and pharmacodynamic data from a preclinical study evaluating the oral delivery of the glucagon-like peptide-1 receptor agonist semaglutide administered via the RaniPill capsule.
